Stephen Connelly net worth and biography

Stephen Connelly Biography and Net Worth

Insider of Equillium

Steve is a co-founder, Director and Chief Scientific Officer of Equillium. Prior to co-founding Equillium, Steve was a Principal at BioMed Ventures, a life sciences venture capital group, where he helped manage a venture portfolio of therapeutic, device and diagnostic companies. Steve joined Biomed Ventures from aTyr where he served as Director of Business Development and Therapeutic Alliances and assisted in raising over $150M through private and public financing’s. Prior to aTyr, he was a Senior Scientist at The Scripps Research Institute, where he worked on multiple drug discovery projects spanning different therapeutic areas, including development work with Vyndaqel®, a first-in-class drug approved for the treatment of familial amyloid neuropathy, and a second-generation inhibitor, AG10, currently in development at Eidos Therapeutics for familial amyloid cardiomyopathy. Steve has an extensive track record conducting novel and innovative research and has published over 30 original scientific papers and patents.

Steve received his Bachelor of Science in Medicinal Chemistry and Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and Master of Business Administration from the Rady School at University of California, San Diego.

What is Stephen Connelly's net worth?: The estimated net worth of Stephen Connelly is at least $710,650.90 as of June 8th, 2021. Dr. Connelly owns 999,509 shares of Equillium stock worth more than $710,651 as of November 23rd. This net worth evaluation does not reflect any other investments that Dr. Connelly may own. Additionally, Dr. Connelly receives a salary of $571,320.00 as Insider at Equillium. Learn More about Stephen Connelly's net worth.
How old is Stephen Connelly?: Dr. Connelly is currently 42 years old. There are 5 older executives and no younger executives at Equillium. The oldest executive at Equillium is Mr. Daniel Mark Bradbury, Executive Chairman, who is 63 years old. Learn More on Stephen Connelly's age.
What is Stephen Connelly's salary?: As the Insider of Equillium, Inc., Dr. Connelly earns $571,320.00 per year. The highest earning executive at Equillium is Mr. Bruce D. Steel C.F.A., Co-Founder, President, CEO & Director, who commands a salary of $779,870.00 per year. Learn More on Stephen Connelly's salary.
How do I contact Stephen Connelly?: The corporate mailing address for Dr. Connelly and other Equillium executives is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. Equillium can also be reached via phone at (858) 240-1200 and via email at [email protected]. Learn More on Stephen Connelly's contact information.
Has Stephen Connelly been buying or selling shares of Equillium?: Stephen Connelly has not been actively trading shares of Equillium in the last ninety days. Most recently, Stephen Connelly sold 8,092 shares of the business's stock in a transaction on Wednesday, October 6th. The shares were sold at an average price of $7.01, for a transaction totalling $56,724.92. Learn More on Stephen Connelly's trading history.
Who are Equillium's active insiders?: Equillium's insider roster includes Stephen Connelly (Insider), and Jason Keyes (CFO). Learn More on Equillium's active insiders.
Are insiders buying or selling shares of Equillium?: In the last twelve months, insiders at the sold shares 7 times. They sold a total of 87,324 shares worth more than $79,932.60. The most recent insider tranaction occured on November, 14th when CFO Jason A Keyes sold 10,000 shares worth more than $7,000.00. Insiders at Equillium own 30.3% of the company. Learn More about insider trades at Equillium.
Information on this page was last updated on 11/14/2024.

Stephen Connelly Insider Trading History at Equillium

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/6/2021	Sell	8,092	$7.01	$56,724.92
6/8/2021	Sell	10,495	$7.18	$75,354.10	999,509
6/4/2021	Sell	13,539	$7.01	$94,908.39	999,509
12/28/2020	Sell	25,000	$4.52	$113,000.00	993,000
9/28/2020	Sell	25,000	$5.62	$140,500.00	1,018,000
7/13/2020	Sell	250,000	$8.13	$2,032,500.00	1,043,000

Stephen Connelly Buying and Selling Activity at Equillium

Equillium Company Overview

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Today's Range

Now: $0.71

$0.70

$0.74

50 Day Range

MA: $0.89

$0.68

$1.38

2 Week Range

Now: $0.71

$0.48

$3.25

Volume

53,877 shs

Average Volume

294,074 shs

Market Capitalization

$25.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

Stephen Connelly Biography and Net Worth

What is Stephen Connelly's net worth?

How old is Stephen Connelly?

What is Stephen Connelly's salary?

How do I contact Stephen Connelly?

Has Stephen Connelly been buying or selling shares of Equillium?

Who are Equillium's active insiders?

Are insiders buying or selling shares of Equillium?